14/03/2019 23:15:17

MAXAR 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Maxar Technologies Inc. - MAXR

NEW ORLEANS, March 14, 2019 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 15, 2019 to file lead plaintiff applications in a securities class action lawsuit against Maxar Technologies Inc. (NYSE: MAXR), if they purchased the Company’s securities between March 29, 2018 and January 7, 2019, inclusive (the “Class Period”).  This action is pending in the United States District Court for the District of Colorado.

What You May Do

If you purchased securities of Maxar and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-maxr/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 15, 2019.

About the Lawsuit

On January 7, 2019, the Company revealed that its WorldView-4 satellite, which generated revenue of roughly $85 million in FY 2018 and had a net book value of about $155 million, could no longer produce usable imagery due to a failure in its control moment gyroscopes causing loss of stability and that it would likely not be recoverable. On this news, the price of Maxar’s shares plummeted.

The case is Durant v. Maxar Technologies, et al., 19-cv-00124

About Kahn Swick & Foti, LLC

KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

lewis.kahn@ksfcounsel.com

1-877-515-1850

1100 Poydras St., Suite 3200

New Orleans, LA 70163

KSF-Logo.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Aug
VELO
Da flere skribenter stadig gerne vil beholde tråden for samling af de mange vigtige informationer o..
44
19 Aug
OMXC25
Endnu en dansk patriark er død. Ære være hans minde.
28
18 Aug
 
Da Berlingske Media for cirka 1 år siden overtog Euroinvestor for 23 mio kr, meddelte de, at nu skul..
22
20 Aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
18 Aug
VELO
Fra anden skribent i Veloxis FB gruppen: Børsen side 4, søndag den 18. august. Et uddrag fra e..
20
21 Aug
I:NDX
Trump er en forretningsmand, der bevæger sig med en forretningsmands hastighed. Han er fløjtende lig..
18
20 Aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
18
19 Aug
OMXC25
En fantastisk dygtig og sympatisk erhvervsmand.  Og en ægte patriot som også betalte sin skat med gl..
17
16 Aug
I:NDX
17
20 Aug
GEN
Lige i dette tilfælde er der måake ikke det vilde nye - men det er stadig data på disse konference d..
15

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
2
MYGN Loss Alert: Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations
3
Bone Therapeutics SA to report half year 2019 results on 30 August 2019
4
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
5
Ambu A/S: Interim report for Q3 2018/19

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 08:43:59
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB5 - 2019-08-22 09:43:59 - 2019-08-22 08:43:59 - 1000 - Website: OKAY